Attempting to stem a significant downturn in its share price, Intercept Pharmaceuticals Inc. told an investor call Sept. 25 that its Phase III REGENERATE study of Ocaliva in non-alcoholic steatohepatitis will continue unaltered despite recent safety concerns about the drug in its already approved indication of primary biliary cholangitis (PBC).
Over a two-day period last week, Intercept’s stock price decreased 38% from $98.59 to $61.59 as US FDA issued a...
Welcome to Scrip
Create an account to read this article
Already a subscriber?